• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Harvard Bioscience Announces Second Quarter 2024 Financial Results

    8/8/24 8:30:00 AM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email

    HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the second quarter ended June 30, 2024.

    Jim Green, Chairman and CEO, said, "Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented during Q2 are expected to drive annualized savings of approximately $4 million while we continue our work on new product development and growth initiatives."

    Green continued, "We believe the market recovery is likely delayed to later in the second half however we remain excited about the long-term growth prospects from our innovative new products."

                   
    Financial Results Summary Three Months Ended June 30, Six Months Ended June 30, 
    (unaudited, $ in millions except per share data)  2024 2023   2024 2023   
    Revenues $23.1   $28.8    $47.6   $58.7   
    Gross margin  57.2%   58.0%    58.8%   59.6%  
    Operating (loss) income (GAAP) $(2.1)  $0.8    $(4.3)  $2.5   
    Adjusted operating income $0.8   $3.6    $2.0   $8.0   
    Net loss (GAAP) $(2.9)  $(1.0)   $(7.6)  $(0.4)  
    Diluted loss per share (GAAP) $(0.07)  $(0.02)   $(0.18)  $(0.01)  
    Diluted adjusted (loss) earnings per share $0.00   $0.04    $0.02   $0.09   
    Adjusted EBITDA $1.3   $3.9    $2.9   $8.7   
    Adjusted EBITDA margin  5.5%   13.6%    6.1%   14.7%  
    Cash flow provided by operations        $0.6   $5.4   
                   

    This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Information" and "Reconciliation of GAAP to Non-GAAP Financial Measures" below.

    Second Quarter 2024 Results

    For the second quarter of fiscal 2024, the Company reported revenues of $23.1 million compared to $28.8 million in the second quarter of fiscal 2023. Gross margin for the three months ended June 30, 2024 was 57.2% compared with 58.0% in the comparable quarter of the prior year. Gross profit was $13.2 million for the second quarter of 2024 compared to $16.7 million in the same period last year. Gross margin below the Company's target of 60% was primarily due to lower absorption of fixed manufacturing costs.

    Net loss for the second quarter of 2024 was $(2.9) million compared to a net loss of $(1.0) million in the second quarter of 2023, which included a loss on marketable securities of ($0.3) million and $(1.6) million in 2024 and 2023, respectively. Net loss was primarily impacted by the dropdown impact of lower revenues. Adjusted EBITDA for the second quarter of 2024 was $1.3 million, compared to $3.9 million in the second quarter of the prior year.

    Six Months Ended June 30, 2024 Results

    For the six months ended June 30, 2024, revenues were $47.6 million, compared to $58.7 million in the same period a year ago. Gross margin for the six months ended June 30, 2024 was 58.8% compared with 59.6% in the comparable period of the prior year. Gross profit was $28.0 million for the first half of 2024 compared to $35.0 million in the same period last year. The reduction in gross margin below the Company's target of 60% was primarily due to lower absorption of fixed manufacturing costs.

    Net loss for the six months ended June 30, 2024 was ($7.6) million compared to a net loss of $(0.4) million in the same period of 2023, primarily due to the dropdown impact of lower revenues. Adjusted EBITDA for the six months ended June 30, 2024 was $2.9 million, compared to adjusted EBITDA of $8.7 million for the comparable period of 2023.

    Cash provided by operations was $0.6 million during the six months ended June 30, 2024 compared to $5.4 million in the same period last year.

    2024 Guidance

    In light of a delayed market recovery, the Company is reducing its full year 2024 revenue outlook to approximately $97 million to $102 million. The Company expects 2024 full year gross margin of approximately 59% to 60% and adjusted EBITDA margin in the high single digits.

    Webcast and Conference Call Details

    In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 10:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to the Company's Investor Relations website shortly before the webcast begins.

    Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.

    Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

    Use of Non-GAAP Financial Information

    In this press release, we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, other operating expenses, loss on equity securities, income taxes, and the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company's operating performance.

    Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.

    With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.

    The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies' non-GAAP financial information.

    About Harvard Bioscience

    Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

    For more information, please visit our website at www.harvardbioscience.com.

    Forward-Looking Statements

    This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, the strength of the Company's market position and business model and anticipated macroeconomic conditions. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company's control. Risks and other factors that could cause the Company's actual results to differ materially from those described its forward-looking statements include those described in the "Risk Factors" section of the Company's most recently filed Annual Report on Form 10-K as well as in the Company's other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company's expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

    Company Contact:Investors Contact:
    Jennifer CoteThree Part Advisors
    Chief Financial OfficerSandy Martin
    (508) 893-3120[email protected]
     (214) 616-2207



                        
    HARVARD BIOSCIENCE, INC.
    Consolidated Statements of Operations
    (unaudited, in thousands, except per share data)
                        
             Three Months Ended Six Months Ended 
             June 30, 2024  June 30, 2023  June 30, 2024  June 30, 2023 
                        
     Revenues$23,097  $28,759  $47,609  $58,734  
     Cost of revenues 9,879   12,086   19,619   23,715  
      Gross profit 13,218   16,673   27,990   35,019  
                        
     Operating expenses:             
      Sales and marketing expenses 5,395   6,178   11,299   12,156  
      General and administrative expenses 5,686   5,353   11,649   11,687  
      Research and development expenses 2,626   2,957   5,511   5,854  
      Amortization of intangible assets 1,331   1,389   2,664   2,777  
      Other operating expenses 249   -   1,215   -  
     Total operating expenses 15,287   15,877   32,338   32,474  
                        
     Operating (loss) income (2,069)  796   (4,348)  2,545  
                        
     Other income (expense):            
      Interest expense (749)  (941)  (1,500)  (1,915) 
      Loss on equity securities (281)  (1,581)  (1,593)  (1,581) 
      Other (expense) income, net (181)  (372)  (323)  60  
     Total other expense (1,211)  (2,894)  (3,416)  (3,436) 
     Loss before income taxes (3,280)  (2,098)  (7,764)  (891) 
     Income tax benefit (353)  (1,118)  (143)  (533) 
     Net loss$(2,927) $(980) $(7,621) $(358) 
                        
     Loss per common share:            
      Basic and diluted$(0.07) $(0.02) $(0.18) $(0.01) 
                        
     Weighted-average common shares:            
      Basic and diluted 43,486   42,354   43,443   42,204  
                        





             
    HARVARD BIOSCIENCE, INC. 
    Condensed Consolidated Balance Sheets 
    (unaudited, in thousands) 
             
             
      June 30, 2024 December 31, 2023  
     Assets       
       Cash and cash equivalents$4,048 $4,283  
       Accounts receivable, net 12,486  16,099  
       Inventories 25,130  24,716  
       Other current assets 4,766  3,940  
               Total current assets 46,430  49,038  
       Property, plant and equipment 4,758  3,981  
       Goodwill and other intangibles 70,068  73,101  
       Other long-term assets 7,656  11,246  
          Total assets$128,912 $137,366  
             
     Liabilities and Stockholders' Equity       
       Current portion, long-term debt$3,720 $5,859  
       Other current liabilities 18,901  20,683  
               Total current liabilities 22,621  26,542  
       Long-term debt, net 31,960  30,704  
       Other long-term liabilities 7,084  7,046  
       Stockholders' equity 67,247  73,074  
          Total liabilities and stockholders' equity$128,912 $137,366  
             





              
    HARVARD BIOSCIENCE, INC.  
    Condensed Consolidated Statements of Cash Flows  
    (unaudited, in thousands)   
              
       Six Months Ended  
        June 30, 2024  June 30, 2023  
     Cash flows from operating activities:        
     Net loss $(7,621) $(358)  
     Adjustments to operating cash flows  8,048   7,101   
     Changes in operating assets and liabilities  130   (1,379)  
     Net cash provided by operating activities  557   5,364   
              
     Cash flows from investing activities:        
     Additions to property, plant and equipment  (1,463)  (741)  
     Acquisition of intangible assets  (223)  (108)  
     Proceeds from sale of product line  -   512   
     Proceeds from sale of marketable equity securities  1,919   -   
     Net cash provided by (used in) investing activities  233   (337)  
              
     Cash flows from financing activities:        
     Borrowing from revolving line of credit  5,550   2,500   
     Repayment of revolving line of credit  (2,550)  (5,450)  
     Repayment of term debt  (4,023)  (2,591)  
     Proceeds from exercise of employee stock options and purchases  204   724   
     Taxes paid related to net share settlement of equity awards  (59)  (451)  
     Net cash used in financing activities  (878)  (5,268)  
              
     Effect of exchange rate changes on cash and cash equivalents  (147)  57   
     Decrease in cash and cash equivalents  (235)  (184)  
     Cash and cash equivalents at the beginning of period  4,283   4,508   
     Cash and cash equivalents at the end of period $4,048  $4,324   
              





     HARVARD BIOSCIENCE, INC. 
     Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) 
     (in thousands, except per share data and percentages) 
            Three Months Ended   Six Months Ended   
            June 30, 2024 June 30, 2023   June 30, 2024 June 30, 2023   
                        
                        
     GAAP operating (loss) income$ (2,069) $ 796    $ (4,348) $ 2,545    
      Stock-based compensation 1,278   1,102     2,326   2,255    
      Acquired asset depreciation & amortization 1,338   1,398     2,676   2,798    
      Other operating expenses (1) 271   -     1,335   -    
      Other adjustments  -   276     -   408    
     Adjusted operating income$ 818  $ 3,572    $ 1,989  $ 8,006    
                        
     Operating margin    (9.0%)  2.8%    (9.1%)  4.3%   
     Adjusted operating margin 3.5%  12.4%    4.2%  13.6%   
                        
                        
     GAAP net loss$ (2,927) $ (980)   $ (7,621) $ (358)   
      Stock-based compensation 1,278   1,102     2,326   2,255    
      Acquired asset depreciation & amortization 1,338   1,398     2,676   2,798    
      Other operating expenses (1) 271   -     1,335   -    
      Other adjustments  -   367     -   4    
      Loss on equity securities 280   1,581     1,593   1,581    
      Income taxes    (36)  (1,776)    591   (2,115)   
     Adjusted net income  204   1,692     900   4,165    
      Depreciation & amortization 464   328     907   649    
      Interest and other expense, net 929   1,222     1,822   2,258    
      Adjusted income taxes (2) (317)  658     (734)  1,582    
     Adjusted EBITDA  $ 1,280  $ 3,900    $ 2,895  $ 8,654    
     Adjusted EBITDA margin 5.5%  13.6%    6.1%  14.7%   
                        
                        
     Diluted loss per share (GAAP)$ (0.07) $ (0.02)   $ (0.18) $ (0.01)   
                        
     Diluted adjusted earnings per share$ 0.00  $ 0.04    $ 0.02  $ 0.09    
     Weighted-average common shares:            
      Diluted GAAP   43,486   42,354     43,443   42,204    
      Diluted Adjusted  44,450   44,656     44,516   44,020    
                        
                        
      (1) Other operating expenses for the three months ended June 30, 2024 includes a credit of $(0.1) million related to an unclaimed property audit and $0.4 million of restructuring-related charges. Other operating expenses for the six months ended June 30, 2024 includes a $0.5 million commission fee paid in connection with the receipt of employee retention credits, a loss of $0.3 million related to an unclaimed property audit, and $0.4 million of restructuring-related charges.   
      (2) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.   





          June 30, 2024 December 31, 2023 
     Debt, including unamortized deferred financing costs $ 35,680  $ 36,563  
     Unamortized deferred financing costs   420   560  
     Cash and cash equivalents   (4,048)  (4,283) 
     Net debt     $ 32,052  $ 32,840  
              





    Primary Logo

    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings

    $HBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces CFO Transition

      HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and Treasurer. Ms. Cote's resignation will be effective upon the filing of the Company's Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote's resignation. Mr. Frost brings over 30 years of financial and executive-level management experience from both private and public companies. He has served as a consultant to the Company since January 2025. Mr. 

      4/10/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

      HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO's website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on

      3/12/25 4:00:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HBIO
    SEC Filings

    See more
    • Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/14/24 4:02:29 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/7/24 4:02:24 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.

      SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      5/8/25 12:45:14 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Harvard Bioscience Inc.

      DEFA14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      4/21/25 4:45:55 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Harvard Bioscience Inc.

      DEF 14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      4/21/25 4:45:39 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Financials

    Live finance-specific insights

    See more
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

      HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, "Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, "We are encouraged by the strong mark

      3/12/25 7:21:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentati

      2/24/25 11:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harvard Bioscience Inc.

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      11/14/24 12:31:23 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Harvard Bioscience Inc.

      SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      3/19/24 1:02:15 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      2/14/24 4:05:25 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

      HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Jim Green, Chairman and CEO said, "Originally joining us as our Vice President of Global Finance, Jennifer brought extensive experience in areas including global financial and operational leadership, corporate strategy, accounting and internal controls, and strong fiscal management. Since assuming the

      6/20/23 8:01:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Harvard Biosci downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight

      4/9/25 8:35:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Biosci upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously

      3/10/23 8:11:48 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • KeyCorp reiterated coverage on Harvard Bioscience with a new price target

      KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously

      3/10/21 5:04:31 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Cote Jennifer covered exercise/tax liability with 5,687 shares, decreasing direct ownership by 3% to 159,019 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      3/21/25 4:50:40 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Green James W covered exercise/tax liability with 38,413 shares, decreasing direct ownership by 1% to 2,845,088 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      3/21/25 4:49:38 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Green James W returned 145,365 shares to the company, decreasing direct ownership by 5% to 2,883,501 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      1/3/25 4:15:27 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials